D. Day

发表

Approaches to modernize the combination drug development paradigm

L. Siu, D. Day, 2016, Genome Medicine.

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

J. Gilbert, D. Day, S. Piha-Paul, 2018, American journal of clinical oncology.

COVID‐19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study

D. Day, K. Webber, A. McCartney, 2022, Asia-Pacific journal of clinical oncology.

Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study

B. Tran, D. Day, L. Spain, 2019, Asia-Pacific journal of clinical oncology.

Hypopharyngeal cancer: looking back, moving forward.

L. Siu, D. Day, A. Hansen, 2016, Current oncology.

Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial

R. Ali, C. Macintyre, D. Day, 2020, JCO global oncology.

Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck.

J. Waldron, B. O'Sullivan, A. Hope, 2020, Oral oncology.

Beta-Testing of Next-Generation DNA Sequencing for Patients With Advanced Cancers Treated at Community Hospitals.

Philippe Bédard, D. Day, 2016, Journal of oncology practice.

Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities

Lisa I. Wang, Philippe Bédard, L. Siu, 2019, Cancer.

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

L. Siu, D. Day, A. Hansen, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The Disease Influenced Vaccine Acceptance Scale-Six (DIVAS-6): Validation of a Measure to Assess Disease-Related COVID-19 Vaccine Attitudes and Concerns

D. Day, B. S. Loe, E. Segelov, 2022, Behavioral medicine.

Atherosclerotic Cardiovascular Risk With Combination Avelumab and Axitinib.

D. Day, Sean Tan, Stephen J. Nicholls, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Synchronous p16+ nasopharyngeal and oropharyngeal squamous cell carcinoma: a case report and review

D. Day, Lachlan McDowell, H. Kua, 2020, Clinical case reports.

Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.

J. Gilbert, D. Day, S. Piha-Paul, 2016 .

Immune Checkpoint Inhibitor Therapy in Oncology

D. Day, S. Nicholls, Sean Tan, 2022, JACC. CardioOncology.

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.

Lee-Anne Stayner, L. Siu, D. Hogg, 2019, European journal of cancer.

Approaches to modernize the combination drug development paradigm

L. Siu, D. Day, 2016, Genome Medicine.

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely

G. Rosner, D. Day, M. Butler, 2017, Clinical Cancer Research.

Current Utility and Future Applications of ctDNA in Colorectal Cancer

D. Day, E. Segelov, Maja M Green, 2018, Advances in the Molecular Understanding of Colorectal Cancer.

Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index

J. Desai, L. Siu, B. Tran, 2019, JNCI cancer spectrum.

D. Day, A. Hansen, 2016, BioDrugs.

Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature

S. Goel, D. Day, G. Hanna, 2020, Translational oncology.

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

C. Rudin, E. Schmidt, H. Pandha, 2023, Journal for ImmunoTherapy of Cancer.

COVID-19 Vaccine Hesitancy in Australian Patients with Solid Organ Cancers

D. Day, K. Webber, M. Nguyen, 2022, medRxiv.

Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia

D. Day, K. Webber, B. Chan, 2022, medRxiv.

Factors Influencing COVID-19 Vaccine Hesitancy among Patients with Serious Chronic Illnesses during the Initial Australian Vaccine Rollout: A Multi-Centre Qualitative Analysis Using the Health Belief Model

D. Day, K. Webber, E. Segelov, 2023, Vaccines.

Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy.

Philippe Bédard, B. Tran, D. Day, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of care for metastatic renal cell carcinoma in Australia

P. Gibbs, N. Lawrentschuk, B. Tran, 2015, BJU international.

Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six‐year experience in a large institution

D. Day, B. Markman, Siddharth Menon, 2020, Cancer reports.

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

D. Day, Lifeng Wang, H. Pan, 2023, Journal for ImmunoTherapy of Cancer.

Endoscopic Ultrasound in Pancreatic Cancer

D. Day, D. Croagh, E. Segelov, 2018, Advances in Pancreatic Cancer.

Chapter 4 Endoscopic Ultrasound in Pancreatic Cancer

D. Day, A. Strickland, D. Croagh, 2018 .

Operational Challenges of an Asia-Pacific Academic Oncology Clinical Trial.

J. Simes, D. Day, H. Toh, 2023, JCO Global Oncology.

The sleep, cancer and rest (SleepCaRe) trial: Rationale and design of a randomized, controlled trial of cognitive behavioral and bright light therapy for insomnia and fatigue in women with breast cancer receiving chemotherapy.

P. Francis, A. Phillips, M. Ftanou, 2022, Contemporary clinical trials.